Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy

The purpose of the study is to assess the safety and efficacy of once daily itacitinib oral administration in participants with diffuse large B-cell lymphoma (DLBCL) who will receive CAR-T cell therapy with axicabtagene ciloleucel (axi-cel).

Trial Details

NCT ID
NCT05757219
Phase
PHASE2
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Itacitinib
  • Chimeric antigen receptor (CAR) T-cell therapy
Locations (sample)
  • Tampa, Florida, United States|27.94752,-82.45843

Key Eligibility Criteria

  • Patients with a histologically confirmed diagnosis of diffuse large B-cell lymphoma (DLBCL) who plan to receive treatment at the Moffitt Cancer Cen…
  • Adult males or females who are 18 years of age or older at time of signing informed consent.
  • Must have ability to comprehend and the willingness to sign written informed consent for study participation.
  • Eligible to receive CAR-T cell therapy (axicabtagene ciloleucel) for DLBCL and histological variants.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →